INTRODUCTION
============

The incidence of chronic graft-versus-host disease (cGVHD) continues to rise as the number of allogeneic stem cell transplants (allo-SCT) has increased to \>25,000 annually worldwide. The utilization of peripheral blood as a preferred stem cell source for allografts may have led to an increased incidence of cGVHD \[[@B1]\]. Aside from being the leading cause of treatment-related mortality among long-term survivors of allo-SCT, it also has a significant impact on quality of life \[[@B2]\]. Corticosteroids remain the backbone for initial cGVHD treatment \[[@B3]\], but overall prognosis remains poor despite a half the patients responding to this therapy. A strict uniform criterion for steroid-refractory disease does not exist but may include progression on prednisone at 1 mg/kg/d for 2 weeks, stable disease at \>0.5 mg/kg/d, and inability to taper prednisone below 0.5 mg/kg/d \[[@B4]\].

There is no consensus regarding the optimal treatment for patients with steroid-refractory cGVHD (SR-cGVHD). Both pharmacologic and non-pharmacologic therapies have been evaluated with limited success. Drugs that have shown some activity include calcineurin inhibitors, tyrosine kinase inhibitors, purine analogs, mammalian target of rapamycin (mTOR) inhibitors, and monoclonal antibodies. Kharfan-Dabaja et al. \[[@B5]\] conducted a systematic review to evaluate the efficacy of rituximab in SR-cGVHD and reported a pooled proportion overall response rate (ORR) of 0.66 (95% confidence interval \[CI\], 0.57-0.74). Among the non-pharmacologic modalities, extracorporeal photopheresis (ECP) has acceptable response rates (RR) in both cutaneous and systematic manifestations of cGVHD \[[@B6], [@B7], [@B8], [@B9], [@B10], [@B11], [@B12]\]. In 2010, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) launched the largest intervention study (BMT CTN \#0801) in cGVHD; a phase II/III trial to compare various treatments including ECP. The ECP arm of the parallel phase II study closed due to slow accrual. Since prospective data on the safety and overall efficacy of ECP with regard to standardized clinical RR and overall survival (OS) consists only of small phase I and phase II trials, we conducted a systematic review and meta-analysis to provide estimates of the overall impact of ECP on SR-cGVHD RR.

MATERIALS AND METHODS
=====================

Study selection
---------------

We included prospective and retrospective studies examining ECP as a treatment for SR-cGVHD. Studies where ECP was given for a minimum of 4 treatments, and which included both acute and cGVHD, were included; however, only the number of patients with cGVHD were included in the analysis. Studies that utilized the addition of calcineurin inhibitors (tacrolimus or cyclosporin) to ECP were included. Case reports and review articles were excluded. Studies with \<5 cGVHD patients were excluded ([Fig. 1](#F1){ref-type="fig"}).

Outcomes
--------

The outcomes measured were complete RR (CRR) and clinical ORR following ECP treatment, including both classical RR and the National Institutes of Health (NIH) cGVHD score \[[@B13], [@B14]\].

Data sources and search strategies
----------------------------------

A comprehensive search of several databases for studies published in any language from 1984 to August 2012 was conducted. The databases searched were: Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, and Scopus. Specific vocabulary supplemented with keywords was used to search for ECP therapy for GVHD, and the results were limited to controlled, prospective, and retrospective studies.

Publication bias
----------------

We searched for unpublished studies using electronic databases from annual meetings or conference abstracts of the American Society of Blood and Marrow Transplantation (ASBMT) from 1990 to 2012, European Group for Blood and Marrow Transplantation (EBMT) from 2000 to 2012, International Society for Pediatric Oncology (SIOP) from 2007 to 2012, and the American Society of Hematology (ASH) from 2001 to 2012. For ongoing trials, the <http://clinicaltrials.gov/> and <http://controlled-trials.com/> databases were searched. We were unable to statistically test for publication bias via funnel plot asymmetry tests due to the small number of studies included and also heterogeneity.

Quality assessment and data extraction
--------------------------------------

Two reviewers (SH and MM) critically appraised the studies from the search results, and also extracted the outcome data independently. Disagreements were resolved by discussion and consensus. The only randomized trial \[[@B15]\] comparing standard therapy to standard therapy and ECP was evaluated using the Cochrane Collaboration\'s tool for risk of assessment bias.

Statistical methods
-------------------

For each study, we estimated the event rate (i.e., cumulative incidence of the outcome at the end of the study follow-up period) and the associated 95% CI. Event rates were pooled across studies using the random effects model. Statistical heterogeneity was assessed using the I^2^ test \[[@B16]\].

RESULTS
=======

Identification of studies
-------------------------

The initial electronic search of multiple electronic databases based on the selection criteria generated 312 studies. Of these, 269 were excluded because of: (a) small sample size of \<5 patients; (b) psoralen plus ultraviolet A (PUVA) treatment was utilized; (c) ECP was used for acute GHVD only. Forty-three studies had cGVHD patients who were treated with ECP, while 25 were excluded because they either did not meet the strict selection criteria or very limited information was available on the RR of the cGVHD patients. Out of 18 studies for analysis, only 4 were prospective trials ([Table 1](#T1){ref-type="table"}). Outcomes from a final sample size of 595 patients were analyzed.

Only 1 randomized controlled trial by Flowers et al. \[[@B15]\] was identified, which compared ECP and conventional therapy to conventional therapy alone in SR-cGVHD. The quality appraisal for this clinical trial using the Cochrane Collaboration\'s tool indicated a low risk of bias considering adequate methodology described for sequence generation, allocation concealment, and for selected outcome reporting.

These findings highlight the problems mentioned by Martin et al. \[[@B17]\], who after a comprehensive review of published reports, also found numerous qualitative deficiencies in studies of secondary treatments for cGVHD. In this report, fewer than 10% published studies tried to minimize selection bias, and investigators in most studies did not use consistent treatment regimens. Similarly in our analysis, different ECP regimen cycles and duration were used, hence we can only report a median number of ECP cycles and median duration of ECP.

Response rates
--------------

CR rates were available from 11 studies with a total of 372 patients ([Table 2](#T2){ref-type="table"}; [Fig. 2](#F2){ref-type="fig"}). Only 3 were prospective studies (N=64). The pooled CR rate for ECP was 29% (CI, 19-42%). There was a significant heterogeneity among the studies (I^2^=79%). ORR were available from 16 studies with a total of 554 patients ([Fig. 3](#F3){ref-type="fig"}). Seven were prospective studies with a total of 64 patients. The pooled ORR of both retrospective and prospective studies was 64% (CI, 65-82%). The 1-year OS rate was available for 4 studies and was 49% (CI, 29-70%). There was a significant heterogeneity among the studies (I^2^=72%).

Efficacy of ECP for skin SR-cGVHD
---------------------------------

Skin was the most commonly involved organ in the selected studies. RR were available for 13 studies with a total of 399 patients and the pooled RR was 74% (CI, 60-85%; I^2^=79%).

Efficacy of ECP for liver SR-cGVHD
----------------------------------

RR were available for 10 studies with a total of 269 patients. The pooled RR was 68% (CI, 57-77%; I^2^=57%).

Efficacy of ECP for ocular SR-cGVHD
-----------------------------------

RR were available from 6 studies with a total of 217 patients. The pooled RR was 60% (CI, 40-78%; I^2^=83%).

Efficacy of ECP for lung SR-cGVHD
---------------------------------

Bronchiolitis obliterans (BO) was the most common presentation of lung cGVHD. RR were available from 5 studies with a total of 156 patients. The pooled RR was 48% (CI, 33-63%; I^2^=62%).

Efficacy of ECP for oral SR-cGVHD
---------------------------------

RR were available from 6 studies with a total of 274 patients. The pooled RR was 72% (CI, 51-86%; I^2^=81%).

Efficacy of ECP for gastrointestinal (GI) tract SR-cGVHD
--------------------------------------------------------

RR were available from 4 studies with a total of 87 patients. The pooled RR was 53% (CI, 21-83%; I^2^=77%).

Efficacy of ECP for musculoskeletal system SR-cGVHD
---------------------------------------------------

RR were available from 3 studies with a total of 72 patients. The pooled RR was 64% (CI, 18-94%; I^2^=88%).

Evaluation of the age effect
----------------------------

We compared the efficacy of ECP in adult and pediatric populations. The pooled CR rate for adults was obtained from 7 studies and was 26% (CI, 14-42%). ORR in adults was available from 11 studies and was 78% (CI, 66-86%). The pooled CR rate for the pediatric population was available from 4 studies and was 39% (CI, 29-51%; *P*=0.17). ORR in pediatric patients was available from 5 studies and was 69% (CI, 58-78%; *P*=0.24). The difference between adults and pediatric CR and ORR was not statistically significant.

DISCUSSION
==========

Although a number of therapeutic modalities have demonstrated responses in SR-cGVHD, most of these treatments do not affect each organ system uniformly. Cellular, pharmacologic, and ECP-based therapies have been evaluated in a cGVHD paradigm and have shown differential results. Mesenchymal stromal cell therapies for GVHD have recently generated considerable interest, but direct clinical experience for SR-cGVHD is limited \[[@B18]\], in contrast to its well-established efficacy in the treatment of acute GVHD \[[@B19]\]. Since ECP has a remarkable safety record in cGVHD treatment and pharmacologic therapies may be associated with significant adverse effects, the efficacy of ECP on organs affected by cGVHD was evaluated systematically to assess all the current evidence for each organ system.

In the final analysis, 18 studies were included, of which 4 were prospective trials. The CR rate following ECP was found to be 29%, whereas the ORR was 64%. A poor 1-year OS of 49% was found in SR-cGVHD patients. We report superior RR following ECP for oral cavity, skin, and liver SR-cGVHD, and a modest RR for SR-cGVHD of the musculoskeletal system, GI tract, eyes, and lungs.

Historically, skin has been reported as the organ most responsive to ECP in SR-cGVHD as shown in [Table 2](#T2){ref-type="table"}, with a RR ranging from 40-100%. Our results indicate that more than two-thirds of patients responded well to ECP, which is consistent with previous studies. Such high RR in skin have been consistently reported only with rituximab \[[@B5]\].

ECP has been reported to have a variable effect on visceral organs involved by cGVHD. For liver cGVHD, Greinix et al. \[[@B20]\] reported a 66% RR following ECP with complete normalization of bilirubin and the transaminases, while Couriel et al. \[[@B10]\] reported a RR of 71% in 15 liver cGVHD patients. Our pooled RR of 68% was consistent with these studies, indicating the efficacy of ECP for liver SR-cGVHD.

BO signifies an extremely poor prognosis in cGVHD patients. Retrospective studies have indicated that ECP primarily stabilizes BO \[[@B21], [@B22]\] and is insufficient to render CR in these patients. Recently Lucid et al. \[[@B22]\] reported the outcome following ECP use and focused specifically on BO after allo-SCT, which yielded a RR of 67% in 9 patients. Our final analysis did not include this study in the pooled results due to a strictly defined selection criterion in the electronic searches. Results from our study, which included 156 patients with BO, indicate that approximately a half of these patients responded to ECP; this is impressive given the futility of most other interventions in highly refractory BO.

The results of the response following ECP for GI tract SR-cGVHD are extremely variable. Perrotti et al. \[[@B23]\] reported that 6 of 8 patients with GI cGVHD responded to ECP, in contrast to Berger et al.\'s report where all 3 patients showed a response \[[@B7]\]. Our meta-analysis indicates a modest response with a half of GI SR-cGVHD patients responding to ECP.

Several limitations of this analysis must be noted; the most important being the absence of uniform criteria for assessment of cGVHD as an endpoint in the studies included. The NIH consensus development project published uniform criteria for the reporting of cGVHD in 2005 \[[@B13]\]. Very few studies published since 2005 have reported outcomes based on these criteria.

The precision of pooled (meta-analytic) effect size is affected by the small sample size of the studies, therefore we performed a meta-analysis to increase power and precision. Only 1 randomized trial for SR-cGVHD and 3 non-randomized prospective studies were found during the literature search. Thus the totality of evidence indicating ECP efficacy remains small and clinicians should address the level of uncertainty about the RR in their discussions with patients.

Most investigators utilized a different schedule of ECP cycles e.g., some studies evaluated RR when ECP was undertaken at a twice weekly schedule, while other studies reported outcomes with initial biweekly therapy.

Despite the above-mentioned limitations, this is the first meta-analysis analyzing the RR following ECP for SR-cGVHD and the estimates provided, despite some uncertainty, are the best available. Shared decision-making strategies using our results may help patients to proceed with options most consistent with their values and preferences.
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Quality of the selected studies.
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^a)^ECP+ Standard therapy, ^b)^Standard therapy, ^c)^mean value.

Abbreviation: ECP, extracorporeal photopheresis.
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Response rates for steroid-refractory chronic graft-versus-host disease.
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Abbreviations: CR, complete response rates; ORR, overall response rates; GI, gastrointestinal; MSK, musculoskeletal; BO, bronchiolitis obliterans.
